academic

Roswell Park Cancer Institute

Account opportunity

Not established

Relationship

Active signals

Trials as sponsor

Why this account matters

Roswell Park Cancer Institute

New trial — CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

New trialNCT07543172

61/100

Opportunity

Commercial fit12/25

Clinical timing20/20

Biomarker need10/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency3/5

New phase 2 trial NCT07543172 posted by Roswell Park Cancer Institute: "CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer". New trial on a phase 2 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 6 days ago.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations

Draft outreach Review

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

Roswell Park Cancer Institute

New trial — EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

New trialNCT06011772

44/100

Opportunity

Commercial fit6/25

Clinical timing16/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New early phase_1 trial NCT06011772 posted by Roswell Park Cancer Institute: "EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer". New trial on a early phase_1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 18 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

Trial	Phase	Testing language
NCT07543172 CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer	phase 2	mol. elig.
NCT06011772 EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	early phase 1	mol. elig.